The DOI matches its Crossref record; 186 of the 186 references it cites were found in a registry or an index.
Cytokines in cancer immunity and immunotherapy
Abstract
Summary: The concept that the immune system recognizes and controls cancer was first postulated over a century ago, and cancer immunity has continued to be vigorously debated and experimentally tested. Mounting evidence in humans and mice supports the involvement of cytokines in tumor initiation, growth, and metastasis. The idea that the immune system detects stressed, transformed, and frankly malignant cells underpins much of the excitement currently surrounding new cytokine therapies in cancer treatment. In this review, we define the contrasting roles that cytokines play in promoting tumor immunity, inflammation, and carcinogenesis. We also discuss the more promising aspects of clinical cytokine use in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862 · cited 1×
“The advantage of using DC vaccines is supported by results in early clinical trials (176, 177).”
ResultCancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
CD1d-Restricted and TCR-Mediated Activation of V α 14 NKT Cells by Glycosylceramides
Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., et al. (1997) · Science · doi:10.1126/science.278.5343.1626 · Cited by 2,400
Trinchieri, G. (1995) · Annual Review of Immunology · doi:10.1146/annurev.iy.13.040195.001343 · Cited by 2,399
The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood
Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S., & Liu, Y.-J. (1999) · Science · doi:10.1126/science.284.5421.1835 · Cited by 2,293
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,094
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Progress in human tumour immunology and immunotherapy
Rosenberg, S. A. (2001) · Nature · doi:10.1038/35077246 · Cited by 1,325
MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis
Coussens, L. M., Tinkle, C. L., Hanahan, D., & Werb, Z. (2000) · Cell · doi:10.1016/s0092-8674(00)00139-2 · Cited by 1,306
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,249
Parrish-Novak, J., Dillon, S. R., Nelson, A., Hammond, A., Sprecher, C., Gross, J. A., Johnston, J., Madden, K., Xu, W., West, J., et al. (2000) · Nature · doi:10.1038/35040504 · Cited by 1,224
Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α
Leibovich, S. J., Polverini, P. J., Shepard, H. M., Wiseman, D. M., Shively, V., & Nuseir, N. (1987) · Nature · doi:10.1038/329630a0 · Cited by 1,210
A Mutation in the Interferon-γ –Receptor Gene and Susceptibility to Mycobacterial Infection
Newport, M. J., Huxley, C. M., Huston, S., Hawrylowicz, C. M., Oostra, B. A., Williamson, R., & Levin, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352602 · Cited by 1,199
Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., & Gately, M. K. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.4.1223 · Cited by 1,197
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Induction of Bystander T Cell Proliferation by Viruses and Type I Interferon in Vivo
Tough, D. F., Borrow, P., & Sprent, J. (1996) · Science · doi:10.1126/science.272.5270.1947 · Cited by 1,077
Fernandez, N. C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., Perricaudet, M., Tursz, T., Maraskovsky, E., & Zitvogel, L. (1999) · Nature Medicine · doi:10.1038/7403 · Cited by 1,060
Rosenberg, S. A., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., & White, D. E. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.15.1159 · Cited by 1,019
Le Bon, A., Schiavoni, G., D'Agostino, G., Gresser, I., Belardelli, F., & Tough, D. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00126-1 · Cited by 974
Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., Caughey, G. H., & Hanahan, D. (1999) · Genes & Development · doi:10.1101/gad.13.11.1382 · Cited by 946
Regulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivator Gene CIITA
Steimle, V., Siegrist, C.-A., Mottet, A., Lisowska-Grospierre, B., & Mach, B. (1994) · Science · doi:10.1126/science.8016643 · Cited by 898 · cited 1×
“IFN-a influences CD8þ T-cell and B-cell adaptive-immune responses (17, 18), by upregulating class I and class II MHC expression (19, 20), and increasing antigen presentation, immune surveillance, and cognate CD8þ T-cell-mediated killing of neoplastic cells (17, 19).”
BackgroundKirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., & Rao, U. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2370 · Cited by 898
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P., Neylan, J., Wilkinson, A., Ekberg, H., Gaston, R., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380304 · Cited by 864
Impairment of Mycobacterial Immunity in Human Interleukin-12 Receptor Deficiency
Altare, F., Durandy, A., Lammas, D., Emile, J.-F., Lamhamedi, S., Le Deist, F., Drysdale, P., Jouanguy, E., Döffinger, R., Bernaudin, F., et al. (1998) · Science · doi:10.1126/science.280.5368.1432 · Cited by 845
Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis
Moore, R. J., Owens, D. M., Stamp, G., Arnott, C., Burke, F., East, N., Holdsworth, H., Turner, L., Rollins, B., Pasparakis, M., et al. (1999) · Nature Medicine · doi:10.1038/10552 · Cited by 839
Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., & Godfrey, D. I. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.661 · Cited by 829
Self-citationBanchereau, J., Palucka, A. K., Dhodapkar, M. V., Burkeholder, S. B., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., et al. (2001) · PubMed · Cited by 806
Wong, G. H. W., Elwell, J. H., Oberley, L. W., & Goeddel, D. V. (1989) · Cell · doi:10.1016/0092-8674(89)90944-6 · Cited by 802
Transforming growth factor-β in T-cell biology
Gorelik, L., & Flavell, R. A. (2002) · Nature Reviews Immunology · doi:10.1038/nri704 · Cited by 792
Takeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., & Okumura, K. (2001) · Nature Medicine · doi:10.1038/83416 · Cited by 775
Self-citationGorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770
Rosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., & Schwarz, S. L. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1169 · Cited by 745
Infections as a major preventable cause of human cancer
Kuper, H., Adami, H. ‐., & Trichopoulos, D. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00742.x · Cited by 740
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.
Angiolillo, A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Maheshwari, S., Kleinman, H. K., Reaman, G. H., & Tosato, G. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.1.155 · Cited by 705
Interleukin-12 in anti-tumor immunity and immunotherapy
Colombo, M. P., & Trinchieri, G. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00032-6 · Cited by 685
Molldrem, J. J., Lee, P. P., Wang, C., Felio, K., Kantarjian, H. M., Champlin, R. E., & Davis, M. M. (2000) · Nature Medicine · doi:10.1038/79526 · Cited by 672
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
Jaiswal, M., LaRusso, N. F., Burgart, L. J., & Gores, G. J. (2000) · PubMed · Cited by 653
A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity
Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J., & Beach, D. H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1375 · Cited by 649 · cited 1×
“MIF is a potent cytokine that overcomes p53 function by suppressing its transcriptional activity (76).”
BackgroundSantini, S. M., Lapenta, C., Logozzi, M., Parlato, S., Spada, M., Di Pucchio, T., & Belardelli, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.10.1777 · Cited by 643
Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.8.622 · Cited by 639
Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. J., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1356 · Cited by 616
Self-citationJaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.145 · Cited by 600
Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., MacGregor, D., Godfrey, D. I., & Trapani, J. A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.755 · Cited by 576
Self-citationPerforin and interferon-γ activities independently control tumor initiation, growth, and metastasis
Street, S. E. A., Cretney, E., & Smyth, M. J. (2001) · Blood · doi:10.1182/blood.v97.1.192 · Cited by 572
Self-citationSoiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. S., Liebster, L., Lam, P., Mentzer, S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13141 · Cited by 571
Pfeffer, L. M., Dinarello, C. A., Herberman, R. B., Williams, B. R. G., Borden, E. C., Bordens, R. W., Walter, M. R., Nagabhushan, T. L., Trotta, P. P., & Pestka, S. (1998) · PubMed · Cited by 549
Trillet-Lenoir, V., Green, J., Manegold, C., Von Pawel, J., Gatzemeier, U., Lebeau, B., Depierre, A., Johnson, P., Decoster, G., Tomita, D., et al. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90376-q · Cited by 543
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L. D., Carbone, D. P., & Gabrilovich, D. I. (1998) · PubMed · Cited by 530
Tumor necrosis factor or tumor promoting factor?
Balkwill, F. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00020-x · Cited by 520
Atkins, M. B., Kunkel, L., Sznol, M., & Rosenberg, S. A. (2000) · PubMed · Cited by 515
Smyth, M. J., Cretney, E., Takeda, K., Wiltrout, R. H., Sedger, L. M., Kayagaki, N., Yagita, H., & Okumura, K. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.661 · Cited by 512
Self-citationNitric oxide and oxygen radicals in infection, inflammation, and cancer.
Maeda, H., & Akaike, T. (1998) · PubMed · Cited by 497
Sidky, Y. A., & Borden, E. C. (1987) · PubMed · Cited by 494
IL-21 Limits NK Cell Responses and Promotes Antigen-Specific T Cell Activation
Kasaian, M. T., Whitters, M. J., Carter, L. L., Lowe, L. D., Jussif, J. M., Deng, B., Johnson, K. A., Witek, J. S., Senices, M., Konz, R. F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00295-9 · Cited by 481
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., & Gabrilovich, D. I. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.3.1224 · Cited by 481
Kayagaki, N., Yamaguchi, N., Nakayama, M., Eto, H., Okumura, K., & Yagita, H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1451 · Cited by 479
Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 465
Self-citationStraus, S. E. (2001) · Blood · doi:10.1182/blood.v98.1.194 · Cited by 464
Chronic Myelogenous Leukemia: Biology and Therapy
Faderl, S., Talpaz, M., Estrov, Z., & Kantarjian, H. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00008 · Cited by 462
Fisher, R. I., Rosenberg, S. A., & Fyfe, G. (2000) · PubMed · Cited by 439
The intriguing role of polymorphonuclear neutrophils in antitumor reactions
Di Carlo, E., Forni, G., Lollini, P., Colombo, M. P., Modesti, A., & Musiani, P. (2001) · Blood · doi:10.1182/blood.v97.2.339 · Cited by 419
Kantarjian, H. M., Smith, T. L., O'Brien, S., Beran, M., Pierce, S., Talpaz, M., & Service*, A. T. L. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-4-199502150-00003 · Cited by 417
Coughlin, C. M., Salhany, K. E., Wysocka, M., Aruga, E., Kurzawa, H., Chang, A. E., Hunter, C. A., Fox, J. C., Trinchieri, G., & Lee, W. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1555 · Cited by 415
Mach, N., Gillessen, S., Wilson, S. B., Sheehan, C., Mihm, M. C., & Dranoff, G. (2000) · PubMed · Cited by 410
Blaser, M. J., Chyou, P.-H., & Nomura, A. M. Y. (1995) · PubMed · Cited by 399
Smyth, M. J., Crowe, N. Y., Pellicci, D. G., Kyparissoudis, K., Kelly, J. M., Takeda, K., Yagita, H., & Godfrey, D. I. (2002) · Blood · doi:10.1182/blood.v99.4.1259 · Cited by 392
Self-citationCoussens, L. M., & Werb, Z. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.f23 · Cited by 384
Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ
Street, S. E. A., Trapani, J. A., MacGregor, D., & Smyth, M. J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020063 · Cited by 375
Self-citationVEGF as a Mediator of Tumor-Associated Immunodeficiency
Ohm, J. E., & Carbone, D. P. (2001) · Immunologic Research · doi:10.1385/ir:23:2-3:263 · Cited by 371
Priming of naive T cells inside tumors leads to eradication of established tumors
Yu, P., Lee, Y., Liu, W., Chin, R. K., Wang, J., Wang, Y., Schietinger, A., Philip, M., Schreiber, H., & Fu, Y.-X. (2004) · Nature Immunology · doi:10.1038/ni1029 · Cited by 356
Tumour necrosis factor α: a potential target for the therapy of solid tumours
Szlosarek, P. W., & Balkwill, F. R. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01196-3 · Cited by 355
Crowe, N. Y., Smyth, M. J., & Godfrey, D. I. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020092 · Cited by 352
Self-citationBiron, C. A. (1998) · Seminars in Immunology · doi:10.1006/smim.1998.0138 · Cited by 341
IL-18 regulates IL-1 β-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1
Vidal-Vanaclocha, F., Fantuzzi, G., Mendoza, L., Fuentes, A. M., Anasagasti, M. J., Martín, J., Carrascal, T., Walsh, P., Reznikov, L. L., Kim, S.-H., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.734 · Cited by 338
Interferon-alpha in tumor immunity and immunotherapy
Belardelli, F., Ferrantini, M., Proietti, E., & Kirkwood, J. M. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00022-3 · Cited by 337
Dranoff, G. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18813.x · Cited by 334
Coughlin, C. M., Salhany, K. E., Gee, M. S., LaTemple, D. C., Kotenko, S., Ma, X., Gri, G., Wysocka, M., Kim, J. E., Liu, L., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80585-3 · Cited by 324
Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes
Rosenberg, S. A., & Lotze, M. T. (1986) · Annual Review of Immunology · doi:10.1146/annurev.iy.04.040186.003341 · Cited by 314
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Seipp, C. A., Einhorn, J. H., White, D. E., & Steinberg, S. M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.968 · Cited by 312
IL-21 Induces the Functional Maturation of Murine NK Cells
Brady, J., Hayakawa, Y., Smyth, M. J., & Nutt, S. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2048 · Cited by 303
Self-citationSuganuma, M., Okabe, S., Marino, M. W., Sakai, A., Sueoka, E., & Fujiki, H. (1999) · PubMed · Cited by 303
Boggio, K., Nicoletti, G., Di Carlo, E., Cavallo, F., Landuzzi, L., Melani, C., Giovarelli, M., Rossi, I., Nanni, P., De Giovanni, C., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.3.589 · Cited by 302
The Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose Dependent
Smyth, M. J., Taniguchi, M., & Street, S. E. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.5.2665 · Cited by 301
Self-citationKnight, B., Yeoh, G. C. T., Husk, K. L., Ly, T., Abraham, L. J., Yu, C., Rhim, J. A., & Fausto, N. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1809 · Cited by 301
Salgia, R., Lynch, T., Skarin, A., Lucca, J., Lynch, C., Jung, K., Hodi, F. S., Jaklitsch, M., Mentzer, S., Swanson, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.091 · Cited by 296
Chronic Myeloid Leukemia Trialists' Collaborative Group (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.21.1616 · Cited by 283
Interleukin-2 and interleukin-15: immunotherapy for cancer
Fehniger, T. A., Cooper, M. A., & Caligiuri, M. A. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00021-1 · Cited by 280
Rook, A. H., Wood, G. S., Yoo, E. K., Elenitsas, R., Kao, D. M. F., Sherman, M. L., Witmer, W. K., Rockwell, K. A., Shane, R. B., Lessin, S. R., et al. (1999) · Blood · doi:10.1182/blood.v94.3.902.415k23_902_908 · Cited by 277
Dinney, C. P., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., BUCANA, C. D., & Fidler, I. J. (1998) · PubMed · Cited by 271
Fellous, M., Nir, U., Wallach, D., Merlin, G., Rubinstein, M., & Revel, M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.10.3082 · Cited by 261
In Vivo Antitumor Activity of Tumor-Infiltrating Lymphocytes Expanded in Recombinant Interleukin-2
(1987) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/79.5.1067 · Cited by 258
Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses
Parrish-Novak, J., Foster, D. C., Holly, R. D., & Clegg, C. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.5.856 · Cited by 256
The Type I Interferon Receptor: Structure, Function, and Evolution of a Family Business
Mogensen, K. E., Lewerenz, M., Reboul, J., Lutfalla, G., & Uzé, G. (1999) · Journal of Interferon & Cytokine Research · doi:10.1089/107999099313019 · Cited by 252
In vivo antitumor activity of interleukin 21 mediated by natural killer cells.
Wang, G., Tschoi, M., Spolski, R. J., Lou, Y., Ozaki, K., Feng, C., Kim, G., Leonard, W. J., & Hwu, P. (2003) · PubMed · Cited by 249
Lee, P., Wang, F., Kuniyoshi, J., Rubio, V., Stuge, T., Groshen, S., Gee, C., Lau, R., Jeffery, G., Margolin, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3836 · Cited by 244
Engle, S. J., Hoying, J. B., Boivin, G. P., Ormsby, I., Gartside, P. S., & Doetschman, T. C. (1999) · PubMed · Cited by 243
Clinical applications of TNF-α in cancer
Lejeune, F. J., Rüegg, C., & Liénard, D. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80226-4 · Cited by 243
Coupling and Uncoupling of Tumor Immunity and Autoimmunity
Bowne, W. B., Srinivasan, R., Wolchok, J. D., Hawkins, W. G., Blachere, N. E., Dyall, R., Lewis, J. J., & Houghton, A. N. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1717 · Cited by 239
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells.
Qin, Z., Schwartzkopff, J., Pradera, F., Kammertoens, T., Seliger, B., Pircher, H., & Blankenstein, T. J. F. (2003) · PubMed · Cited by 235
Role of transforming growth factor beta in cancer
Pasche, B. (2001) · Journal of Cellular Physiology · doi:10.1002/1097-4652(200002)186:2<153::aid-jcp1016>3.0.co;2-j · Cited by 235
The Fas counterattack: Cancer as a site of immune privilege
O’Connell, J., Bennett, M. W., O’Sullivan, G. C., Collins, J. K., & Shanahan, F. (1999) · Immunology Today · doi:10.1016/s0167-5699(98)01382-6 · Cited by 232 · cited 1×
“Tumor cells have been shown to acquire the expression of FasL and use it for delivering death signals in activated, Fas-positive T cells (116).”
BackgroundFas expression and function in normal and malignant breast cell lines.
Keane, M., Ettenberg, S. A., Lowrey, G. A., RUSSELL, E. K., & Lipkowitz, S. (1996) · PubMed · Cited by 231
Nanni, P., Nicoletti, G., De Giovanni, C., Landuzzi, L., Di Carlo, E., Cavallo, F., Pupa, S. M., Rossi, I., Colombo, M. P., Ricci, C., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.9.1195 · Cited by 230
Scholl, S. M., Pallud, C., Beuvon, F., Hacene, K., Stanley, E. R., Rohrschneider, L., Tang, R., Pouillart, P., & Lidereau, R. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.2.120 · Cited by 226
Correction: The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer
El-Omar, E. M., Carrington, M., Chow, W.-H., McColl, K. E. L., Bream, J. H., Young, H. A., Herrera, J., Lissowska, J., Yuan, C.-C., Rothman, N., et al. (2001) · Nature · doi:10.1038/35083631 · Cited by 217
Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.
Noguchi, Y., Richards, E. C., Chen, Y. T., & Old, L. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.6.2219 · Cited by 212
Interleukin-1—a major pleiotropic cytokine in tumor–host interactions
Apte, R. N., & Voronov, E. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00014-7 · Cited by 212
Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice.
Engle, S. J., Ormsby, I., Pawlowski, S. A., Boivin, G. P., Croft, J., Balish, E., & Doetschman, T. C. (2002) · PubMed · Cited by 211
Waldmann, T., White, J., Goldman, C., Top, L., Grant, A., Bamford, R., Roessler, E., Horak, I., Zaknoen, S., & Kasten-Sportes, C. (1993) · Blood · doi:10.1182/blood.v82.6.1701.1701 · Cited by 208
Wu, S. M., Boyer, C. M., Whitaker, R. S., Berchuck, A., Wiener, J. R., Weinberg, J. B., & Bast, R. C. (1993) · PubMed · Cited by 208
Finkelman, F. D., Svetic, A., Gresser, I., Snapper, C., Holmes, J., Trotta, P. P., Katona, I. M., & Gause, W. C. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.5.1179 · Cited by 190
Spontaneous Development of Plasmacytoid Tumors in Mice with Defective Fas–Fas Ligand Interactions
Davidson, W. F., Giese, T., & Fredrickson, T. N. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1825 · Cited by 189
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Sznol, M., Schwarz, S. L., Spiess, P. J., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1690 · Cited by 185
Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer
Enzler, T., Gillessen, S., Manis, J. P., Ferguson, D., Fleming, J., Alt, F. W., Mihm, M., & Dranoff, G. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021258 · Cited by 179
Tumour necrosis factor-α in Barrett's oesophagus: a potential novel mechanism of action
Tselepis, C., Perry, I., Dawson, C., Hardy, R., Darnton, S. J., McConkey, C., Stuart, R. C., Wright, N., Harrison, R., & Jankowski, J. A. Z. (2002) · Oncogene · doi:10.1038/sj.onc.1205731 · Cited by 174
Antitumor and Antimetastatic Activity of IL-23
Lo, C.-H., Lee, S.-C., Wu, P.-Y., Pan, W.-Y., Su, J., Cheng, C.-W., Roffler, S. R., Chiang, B.-L., Lee, C.-N., Wu, C.-W., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.600 · Cited by 171
Smyth, M. J., Kelly, J. M., Baxter, A. G., Körner, H., & Sedgwick, J. D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1611 · Cited by 165
Self-citationT cells require TRAIL for optimal graft-versus-tumor activity
Schmaltz, C., Alpdogan, O., Kappel, B. J., Muriglan, S. J., Rotolo, J. A., Ongchin, J., Willis, L. M., Greenberg, A. S., Eng, J. M., Crawford, J. M., et al. (2002) · Nature Medicine · doi:10.1038/nm1202-797 · Cited by 163
Ma, H.-L., Whitters, M. J., Konz, R. F., Senices, M., Young, D. A., Grusby, M. J., Collins, M., & Dunussi-Joannopoulos, K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.608 · Cited by 162
CSF-1 and Its Receptor in Ovarian, Endometrial and Breast Cancer
Kacinski, B. M. (1995) · Annals of Medicine · doi:10.3109/07853899509031941 · Cited by 162
α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis
Hayakawa, Y., Rovero, S., Forni, G., & Smyth, M. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1630663100 · Cited by 159
Self-citationCytokines, tumour-cell death and immunogenicity: a question of choice
Musiani, P., Modesti, A., Giovarelli, M., Cavallo, F., Forni, G., Lollini, P. L., & Colombo, M. P. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80012-6 · Cited by 159
Ferbas, J., Toso, J. F., Logar, A., Navratil, J. S., & Rinaldo, C. R. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.9.4649 · Cited by 146
Vidal‐Vanaclocha, F., Amezaga, C. A. V.-D., Asumendi, A., Kaplanski, G., & Dinarello, C. A. (1994) · PubMed · Cited by 146
Wigginton, J. M., Gruys, E., Geiselhart, L., Subleski, J. J., Komschlies, K. L., Park, J., Wiltrout, T. A., Nagashima, K., Back, T. C., & Wiltrout, R. H. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10128 · Cited by 146
Wu, C. J., Yang, X., McLaughlin, S., Neuberg, D. S., Canning, C. M., Stein, B. L., Alyea, E. P., Soiffer, R. J., Dranoff, G., & Ritz, J. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10196 · Cited by 145
Effect of interleukin 12 on tumor induction by 3-methylcholanthrene.
Noguchi, Y., Jungbluth, A., Richards, E. C., & Old, L. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11798 · Cited by 143
The use of antibodies against the IL-2 receptor in transplantation.
Waldmann, T., & O'Shea, J. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80215-x · Cited by 139
Gene Transfer as Cancer Therapy
Dranoff, G., & Mulligan, R. C. (1995) · Advances in immunology · doi:10.1016/s0065-2776(08)60624-0 · Cited by 135
Interferon Induces Natural Killer Cell Blastogenesis In Vivo
Biron, C. A., Sonnenfeld, G., & Welsh, R. M. (1984) · Journal of Leukocyte Biology · doi:10.1002/jlb.35.1.31 · Cited by 129
Morse, M. A., Nair, S. K., Fernandez-Casal, M., Deng, Y., Peter, M. S., Williams, R., Hobeika, A. C., Mosca, P. J., Clay, T. M., Cumming, R. I., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3883 · Cited by 127
Nowicki, A., Szenajch, J., Ostrowska, G., Wójtowicz, A., Wójtowicz, K., Kruszewski, A. A., Maruszyński, M., Aukerman, S. L., & Wiktor-Jędrzejczak, W. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960103)65:1<112::aid-ijc19>3.0.co;2-i · Cited by 123
Battegay, E., Raines, E. W., Colbert, T., & Ross, R. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.11.6040 · Cited by 120
Kitakata, H., Nemoto‐Sasaki, Y., Takahashi, Y., Kondo, T., Mai, M., & Mukaida, N. (2002) · PubMed · Cited by 118
Cutting Edge: Differentiation of Antitumor CTL In Vivo Requires Host Expression of Stat1
Fallarino, F., & Gajewski, T. F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4109 · Cited by 118
Vidal‐Vanaclocha, F., Alvarez, A., Asumendi, A., Urcelay, B., Tonino, P., & Dinarello, C. A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.3-4.198 · Cited by 117
Gajewski, T. F., Fallarino, F., Ashikari, A., & Sherman, M. E. (2001) · PubMed · Cited by 113
The N-terminal propiece of interleukin 1α is a transforming nuclear oncoprotein
Stevenson, F. T., Turck, J., Locksley, R. M., & Lovett, D. H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.508 · Cited by 113
Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.
(1997) · Europe PMC (PubMed Central) · Cited by 111
Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.
Rosenberg, S. A. (2000) · PubMed · Cited by 109
Tumor necrosis factor stimulates epithelial tumor cell motility.
Rosen, E. M., Goldberg, I. D., Liu, D., Setter, E., Donovan, M. A., Bhargava, M., Reiss, M., & Kacinski, B. M. (1991) · PubMed · Cited by 107
Regulation of monocyte MMP-9 production by TNF-α and a tumour-derived soluble factor (MMPSF)
Leber, T., & Balkwill, F. R. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.568 · Cited by 107
Clinical significance of the determination of angiogenic factors
Toi, M., Taniguchi, T., Yamamoto, Y., Kurisaki, T., Suzuki, H., & Tominaga, T. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00397-8 · Cited by 107
Mortarini, R., Borri, A., Tragni, G., Bersani, I., Vegetti, C., Bajetta, E., Pilotti, S., Cerundolo, V., & Anichini, A. (2000) · PubMed · Cited by 105
Endogenous type I interferons as a defense against tumors
Gresser, I., & Belardelli, F. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00035-1 · Cited by 105
Tumor necrosis factor α release is a major biological event associated with rituximab treatment
Bienvenu, J., Chvetzoff, R., Salles, G., Balter, C., Tilly, H., Herbrecht, R., Morel, P., Lederlin, P., Solal‐Céligny, P., Audhuy, B., et al. (2001) · The Hematology Journal · doi:10.1038/sj.thj.6200133 · Cited by 100
Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice.
Hayashi, T., & Faustman, D. L. (2002) · PubMed · Cited by 97
Weichselbaum, R. R., Kufe, D. W., Hellmän, S., Rasmussen, H. S., King, C. R., Fischer, P. H., & Mauceri, H. J. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00900-2 · Cited by 82
Shepherd, F. A., Beaulieu, R., Gelmon, K. E., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1736 · Cited by 79
Won, J., Kim, H., Park, E. J., Hong, Y., Kim, S., & Yun, Y. (1999) · PubMed · Cited by 76
Countering the 'counterattack' hypothesis
Restifo, N. P. (2001) · Nature Medicine · doi:10.1038/85357 · Cited by 74
Ferrantini, M., & Belardelli, F. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0333 · Cited by 72
Marroquin, C. E., Westwood, J. A., Lapointe, R., Mixon, A., Wunderlich, J. R., Caron, D. A., Rosenberg, S. A., & Hwu, P. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200205000-00011 · Cited by 70
IFN induction and associated changes in splenic leukocyte distribution
Ishikawa, R., & Biron, C. A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.9.3713 · Cited by 65
The future of interleukin-2: enhancing therapeutic anticancer vaccines.
Overwijk, W. W., Theoret, M. R., & Restifo, N. P. (2000) · PubMed · Cited by 63
Tomimatsu, S., Ichikura, T., & Mochizuki, H. (2001) · Cancer · doi:10.1002/1097-0142(20010401)91:7<1272::aid-cncr1128>3.0.co;2-z · Cited by 63
Modulation of Apo‐1/Fas (CD95)‐induced programmed cell death in myeloma cells by interferon‐α2
Egle, A., Villunger, A., Kos, M., Böck, G., Gruber, J., Auer, B., & Greil, R. (1996) · European Journal of Immunology · doi:10.1002/eji.1830261244 · Cited by 61
Cytokines in non-genotoxic hepatocarcinogenesis
Roberts, R. A., & Kimber, I. (1999) · Carcinogenesis · doi:10.1093/carcin/20.8.1397 · Cited by 61
Belardelli, F., Ferrantini, M., Santini, S. M., Baccarini, S., Proietti, E., Colombo, M. P., Sprent, J., & Tough, D. F. (1998) · PubMed · Cited by 50
Antagonistic effects of interferons on the cytotoxicity mediated by natural killer cells.
Trinchieri, G., Santoli, D., Granato, D., & PERUSSIA, B. (1981) · PubMed · Cited by 45
TNF-α targeted therapeutic approaches in patients with hematologic malignancies
Tsimberidou, A. M., & Giles, F. J. (2002) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2.3.277 · Cited by 35
Interleukin-1 receptor antagonist mRNA expression and the progression of gastric carcinoma
Iizuka, N., Hazama, S., Hirose, K., Abe, T., Tokuda, N., Fukumoto, T., Tangoku, A., & Oka, M. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00162-7 · Cited by 34
Taguchi, Y., Purtilo, D. T., & Okano, M. (1994) · Transplantation · doi:10.1097/00007890-199457120-00023 · Cited by 30
Ahmed, R. (1996) · Science · doi:10.1126/science.272.5270.1904 · Cited by 29
Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase.
Guilhot, F., & Lacotte‐Thierry, L. (1998) · PubMed · Cited by 27
Taguchi, Y., Purtilo, D. T., & Okano, M. (1994) · PubMed · Cited by 25
Gene Regulation and Clinical Roles for Interferons in Neoplastic Diseases
Borden, E. C. (1998) · The Oncologist · doi:10.1634/theoncologist.3-3-198 · Cited by 19
Baharians, Z., & Schönthal, A. H. (1999) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199904)24:4<276::aid-mc5>3.0.co;2-# · Cited by 18
Update on the role of adjuvant interferon for high risk melanoma.
Agarwala, S. S., & Kirkwood, J. M. (2000) · PubMed · Cited by 18
Dendritic cells in models of tumor immunity. Role of Flt3 ligand
Maliszewski, C. R. (2001) · Pathologie Biologie · doi:10.1016/s0369-8114(01)00172-9 · Cited by 13
Vanhamme, L., Marshall, G. M., Schuh, A. C., Breitman, M. L., & Vogt, P. K. (1993) · PubMed · Cited by 12
Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6
(2000) · Pure Amsterdam UMC · doi:10.1002/1521-4141(200007)30:7 · Cited by 1
Cited by
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940
Singh, N., Baby, D., Rajguru, J., Patil, P., Thakkannavar, S., & Pujari, V. (2019) · Annals of African Medicine · doi:10.4103/aam.aam_56_18 · Cited by 1,333
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Inflammation and cancer: An ancient link with novel potentials
Perwez Hussain, S., & Harris, C. C. (2007) · International Journal of Cancer · doi:10.1002/ijc.23173 · Cited by 1,097
Inflammation, a Key Event in Cancer Development
Lu, H., Ouyang, W., & Huang, C. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0261 · Cited by 1,028
Metadata
- Authors
- Smyth, M. J., Cretney, E., Kershaw, M. H., & Hayakawa, Y.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2004-11-11
- Volume
- 202
- Issue
- 1
- Pages
- 275-293
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2094637933
- Cited by
- 412
- References
- 186
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.